Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones
Portfolio Pulse from
Rhythm Pharmaceuticals reported preliminary unaudited net revenues of $42 million for Q4 2024 and $130 million for the full year from global sales of IMCIVREE. The company is on track to report topline data from a Phase 3 trial in the first half of 2025.
January 10, 2025 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals announced preliminary revenues of $42M for Q4 2024 and $130M for the full year from IMCIVREE sales. The company is progressing with its Phase 3 trial, with results expected in H1 2025.
The reported revenues indicate strong sales performance, which is positive for the stock. Additionally, the upcoming Phase 3 trial results could further impact the stock positively if the data is favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100